TW201536766A - 3-(5-胺基-2-甲基-4-氧代喹唑啉-3(4h)-基)六氫吡啶-2,6-二酮之合成 - Google Patents

3-(5-胺基-2-甲基-4-氧代喹唑啉-3(4h)-基)六氫吡啶-2,6-二酮之合成 Download PDF

Info

Publication number
TW201536766A
TW201536766A TW103115643A TW103115643A TW201536766A TW 201536766 A TW201536766 A TW 201536766A TW 103115643 A TW103115643 A TW 103115643A TW 103115643 A TW103115643 A TW 103115643A TW 201536766 A TW201536766 A TW 201536766A
Authority
TW
Taiwan
Prior art keywords
methyl
dione
hexahydropyridine
nitro
certain embodiments
Prior art date
Application number
TW103115643A
Other languages
English (en)
Chinese (zh)
Inventor
Alexander L Ruchelman
Benjamin M Cohen
Anusuya Choudhury
Matthew M Kreilein
William W Leong
Hon-Wah Man
Original Assignee
Celgene Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celgene Corp filed Critical Celgene Corp
Publication of TW201536766A publication Critical patent/TW201536766A/zh

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
TW103115643A 2013-05-01 2014-04-30 3-(5-胺基-2-甲基-4-氧代喹唑啉-3(4h)-基)六氫吡啶-2,6-二酮之合成 TW201536766A (zh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361818254P 2013-05-01 2013-05-01

Publications (1)

Publication Number Publication Date
TW201536766A true TW201536766A (zh) 2015-10-01

Family

ID=50885008

Family Applications (1)

Application Number Title Priority Date Filing Date
TW103115643A TW201536766A (zh) 2013-05-01 2014-04-30 3-(5-胺基-2-甲基-4-氧代喹唑啉-3(4h)-基)六氫吡啶-2,6-二酮之合成

Country Status (26)

Country Link
US (3) US9067912B2 (enExample)
EP (2) EP3199532A1 (enExample)
JP (2) JP6490055B2 (enExample)
KR (1) KR20160003228A (enExample)
CN (2) CN105377831B (enExample)
AR (1) AR096165A1 (enExample)
AU (2) AU2014260011A1 (enExample)
CA (1) CA2910971A1 (enExample)
CY (1) CY1119525T1 (enExample)
DK (1) DK2991976T3 (enExample)
ES (1) ES2645944T3 (enExample)
HR (1) HRP20171535T1 (enExample)
HU (1) HUE034770T2 (enExample)
LT (1) LT2991976T (enExample)
MX (1) MX363652B (enExample)
NZ (1) NZ628322A (enExample)
PH (1) PH12015502477A1 (enExample)
PL (1) PL2991976T3 (enExample)
PT (1) PT2991976T (enExample)
RS (1) RS56565B1 (enExample)
RU (1) RU2015151359A (enExample)
SG (1) SG11201508836XA (enExample)
SI (1) SI2991976T1 (enExample)
SM (1) SMT201700513T1 (enExample)
TW (1) TW201536766A (enExample)
WO (1) WO2014179416A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS52349B (sr) 2006-09-26 2012-12-31 Celgene Corporation 5-supstituisani derivati hinazolinona kao antitumorski agensi
CA2829570C (en) 2011-03-11 2019-05-07 Celgene Corporation Solid forms of 3-(5-amino-2-methyl-4-oxo-4h-quinazolin-3-yl)-piperidine-2,6-dione, and their pharmaceutical compositions and uses
EP2892887B1 (en) 2012-09-04 2020-07-15 Celgene Corporation Isotopologues of 3-(5-amino-2-methyl-4-oxoquinazolin-3(4h)-yl) piperidine-2-6-dione and methods of preparation thereof
US10973822B2 (en) 2015-07-02 2021-04-13 Celgene Corporation Combination therapy for treatment of hematological cancers and solid tumors
CN106083622B (zh) * 2016-06-16 2018-06-19 常州齐晖药业有限公司 一种甲苯咪唑中间体3,4-二氨基二苯甲酮的制备方法
US20180258064A1 (en) * 2017-03-07 2018-09-13 Celgene Corporation Solid forms of 3-(5-amino-2-methyl-4-oxo-4h-quinazolin-3-yl)-piperidine-2,6-dione, and their pharmaceutical compositions and uses
CN113101295A (zh) * 2020-03-20 2021-07-13 上海疆云医疗健康科技有限公司 二苯乙烯类似物在治疗糖尿病肾脏疾病中的用途
KR20240055046A (ko) * 2021-09-02 2024-04-26 신톤 비.브이. 오시머티닙을 제조하는 방법

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2032538A2 (en) * 2006-06-08 2009-03-11 Array Biopharma, Inc. Quinoline compounds and methods of use
RS52349B (sr) * 2006-09-26 2012-12-31 Celgene Corporation 5-supstituisani derivati hinazolinona kao antitumorski agensi
RU2017120977A (ru) * 2011-03-11 2018-11-15 Селджин Корпорейшн Способ лечения рака с использованием 3-(5-амино-2-метил-4-оксо-4h-хиназолин-3-ил)пиперидин-2,6-диона
CA2829570C (en) * 2011-03-11 2019-05-07 Celgene Corporation Solid forms of 3-(5-amino-2-methyl-4-oxo-4h-quinazolin-3-yl)-piperidine-2,6-dione, and their pharmaceutical compositions and uses
EP2892887B1 (en) * 2012-09-04 2020-07-15 Celgene Corporation Isotopologues of 3-(5-amino-2-methyl-4-oxoquinazolin-3(4h)-yl) piperidine-2-6-dione and methods of preparation thereof
EP2943201B2 (en) * 2013-01-14 2020-07-29 Deuterx, LLC 3-(5-substituted-4-oxoquinazolin-3(4h)-yl)-3-deutero-piperidine-2,6-dione derivatives

Also Published As

Publication number Publication date
RS56565B1 (sr) 2018-02-28
NZ628322A (en) 2017-06-30
CN107935994A (zh) 2018-04-20
US9303014B2 (en) 2016-04-05
CN105377831B (zh) 2018-02-02
KR20160003228A (ko) 2016-01-08
JP6490055B2 (ja) 2019-03-27
RU2015151359A (ru) 2017-06-06
MX2015015073A (es) 2016-03-03
EP2991976A1 (en) 2016-03-09
SI2991976T1 (sl) 2017-11-30
LT2991976T (lt) 2017-10-25
CA2910971A1 (en) 2014-11-06
CN105377831A (zh) 2016-03-02
JP2019069958A (ja) 2019-05-09
SMT201700513T1 (it) 2018-01-11
US20150274694A1 (en) 2015-10-01
US9067912B2 (en) 2015-06-30
US9266858B2 (en) 2016-02-23
PH12015502477A1 (en) 2016-02-22
MX363652B (es) 2019-03-28
AR096165A1 (es) 2015-12-09
ES2645944T3 (es) 2017-12-11
WO2014179416A1 (en) 2014-11-06
US20140330016A1 (en) 2014-11-06
EP3199532A1 (en) 2017-08-02
HUE034770T2 (hu) 2018-02-28
PT2991976T (pt) 2017-11-14
CY1119525T1 (el) 2018-03-07
HRP20171535T1 (hr) 2017-11-17
EP2991976B1 (en) 2017-09-20
PL2991976T3 (pl) 2018-01-31
SG11201508836XA (en) 2015-11-27
US20160009685A1 (en) 2016-01-14
JP2016517886A (ja) 2016-06-20
AU2017200965A1 (en) 2017-03-02
DK2991976T3 (da) 2017-11-06
AU2014260011A1 (en) 2015-11-12

Similar Documents

Publication Publication Date Title
TW201536766A (zh) 3-(5-胺基-2-甲基-4-氧代喹唑啉-3(4h)-基)六氫吡啶-2,6-二酮之合成
AU2018380426B2 (en) Processes for making modulators of cystic fibrosis transmembrane conductance regulator
CN108925135A (zh) 制备(S)-(2R,3R,11bR)-3-异丁基-9,10-二甲氧基-2,3,4,6,7,11b-六氢-1H-吡啶并[2,1-a]异喹啉-2-基2-氨基-3-甲基丁酸酯二(4-甲基苯磺酸盐)的合成方法
JP6055817B2 (ja) ナフチリジンの調製方法
JP2022520698A (ja) 3-メチル-1,2,4-チアジアゾール-5-カルボヒドラジドまたはそのメチル-d3重水素化形態の合成
KR20180022125A (ko) 디아민 유도체의 산부가염 및 이의 제조 방법
TWI605045B (zh) 殺線蟲磺醯胺之製備
CN105073752A (zh) 制备三环化合物的方法以及可通过所述制备方法制备的三环化合物
CN114907315B (zh) Selitrectinib中间体的合成方法
CN108473510B (zh) 制备2-吡唑并[1,5-a]吡嗪-2-基吡啶并[1,2-a]嘧啶-4-酮的方法
KR20190039087A (ko) 정제된 세니크리비록 및 세니크리비록을 제조하기 위한 정제된 중간체
HK40051429B (zh) 四环化合物的制备方法
CN114644629A (zh) 一种[1,2,4]三唑并[1,5-a]吡啶类化合物的合成方法
CN109982997A (zh) 3-(吡啶基-2-氨基)丙腈及其类似物的制造方法